Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1421-9875|32|6|733-739

ISSN： 0257-2753

Source： Digestive Diseases, Vol.32, Iss.6, 2014-10, pp. : 733-739

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment

By  

Liver Cancer, Vol. 5, Iss. 4, 2016-09 ,pp. : 257-268

Karger

Access to resources Recommend Favorite

Duration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

By  

Digestive Diseases, Vol. 32, Iss. 6, 2014-10 ,pp. : 705-710

Karger

Access to resources Recommend Favorite

Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis

By  

Digestion, Vol. 83, Iss. 4, 2011-02 ,pp. : 275-282

Karger

Access to resources Recommend Favorite

The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization

By  

Liver Cancer, Vol. 6, Iss. 3, 2017-05 ,pp. : 227-235

Karger

Access to resources Recommend Favorite

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

By Ogasawara Sadahisa  

Hepatology International, Vol. 5, Iss. 3, 2011-09 ,pp. : 850-856

Springer Publishing Company

Access to resources Recommend Favorite